Cabozantinib for Unresectable and Progressive Metastatic Phaeochromocytoma or Paraganglioma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Cabozantinib in patients with unresectable and progressive metastatic phaeochromocytoma or paraganglioma (the Natalie Trial): a single-arm, phase 2 trial
Lancet Oncol 2024 May 01;25(5)658-667, C Jimenez, MA Habra, MT Campbell, G Tamsen, D Cruz-Goldberg, J Long, R Bassett, R Dantzer, V Balderrama-Brondani, J Varghese, Y LuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.